Eli Lilly and Company

Eli Lilly and Company

LLYNYSE / NASDAQHealthcareLarge cap

$1,347.11-$4.01 (-0.3%)

Last close · Data as of Nov 20, 2026

Market cap
$1.00T
P/E
48.6x
EV / EBITDA
32.8x
Revenue
$65.2B
Net margin
31.7%
ROCE
38.4%

+29.1% over the last year

Eli Lilly and Company price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+4.9%
3M
+8.3%
6M
+32.2%
1Y
+29.1%
5Y
+416.7%

52-week range

Day change -$4.01 (-0.3%) from $1,351 to $1,347 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in LLY, bought on each weekday since 2021.

News & filings

What Eli Lilly and Company filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 38.0 times interest costs.

Concerns (1)

  • The P/E of 48.6 is 101% above the peer median of 24.2.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

Read moreShow less

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Sector
Healthcare
Shares outstanding
894.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.00T
P/E
48.6x
P/B
37.8x
EV / EBITDA
32.8x
EV / Sales
15.9x
P/S
15.4x
52-week high
$1,443.50
52-week low
$851.21

Profitability

Operating margin
45.6%
Net margin
31.7%
EBITDA margin
48.6%
ROE
77.8%
ROCE
38.4%
ROA
18.4%
Asset turnover
0.58

Growth

Revenue
$65.2B
Revenue growth, 1Y
44.7%
Revenue CAGR, 3Y
31.7%
Net profit growth, 1Y
94.9%
Free cash flow
$6.0B

Solvency

Current ratio
1.58
Debt / Equity
1.60
Debt / Assets
0.38
CFO / Net profit
0.81
Cash / Market cap
0.7%

Where the revenue went

Of every $100 of FY2025 revenue, $32 was left as net income.

Eli Lilly and Company income statement flow, FY2025
Eli Lilly and Company income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$11.1B
RevenueGross profit$54.1B
Gross profitResearch and development$13.3B
Gross profitSelling, general and administrative$11.1B
Gross profitOperating income$29.7B
Operating incomePretax income$25.7B
Operating incomeInterest and other expense$4.0B
Pretax incomeTax and other$5.1B
Pretax incomeNet income$20.6B

Revenue and net profit

Revenue grew 44.7% in FY2025; net profit is the dashed line.

Eli Lilly and Company revenue and net profit by fiscal year
Eli Lilly and Company revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$28.5B$6.2B
FY2023$34.1B$5.2B
FY2024$45.0B$10.6B
FY2025$65.2B$20.6B

Cash flows

FY2025: $16.8B from operations, $6.0B free after investment (dashed).

Eli Lilly and Company operating and free cash flow by fiscal year
Eli Lilly and Company operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$7.6B$4.6B
FY2023$4.2B-$3.2B
FY2024$8.8B$414.0M
FY2025$16.8B$6.0B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$65.2B+44.7%1Y
EBITDA
$31.7B+68.5%1Y
Net profit
$20.6B+94.9%1Y
Cash from operations
$16.8B+90.7%1Y
Free cash flow
$6.0B+1,340.6%1Y
Revenue CAGR, 3Y
31.7%
Net profit CAGR, 3Y
49.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$65.2B$31.7B$20.6B$6.0B77.8%+44.7%+94.9%

Monthly returns

Month-by-month returns of LLY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$112.5B
Liabilities$85.9B
Equity$26.5B
Paid-in capital$7.3B
Retained earnings$24.5B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; LLY highlighted.

P/E against peers

LLY trades at 48.6x earnings against a peer median of 24.2x (a 101% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Eli Lilly and CompanyLLYthis companyP/E ↑ premium$1.00T48.6x37.8x77.8%32.8x
Johnson & JohnsonJNJ$549.3B20.5x6.7x32.9%14.1x
AbbVie Inc.ABBV$397.4B94.9x—-128.0%26.1x
UnitedHealth Group IncorporatedUNH$360.1B29.9x3.8x12.8%18.0x
Merck & Co., Inc.MRK$297.0B16.3x5.6x34.7%11.7x
Amgen Inc.AMGN$186.5B24.2x21.5x89.1%13.7x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Peer median—24.2x5.6x22.8%13.9x

Year-to-date ROI

LLY since 1 January, against earlier years.

Historical volatility

LLY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Eli Lilly and Company operating margin by fiscal year
Eli Lilly and Company operating margin by fiscal year
DateOperating margin
FY202229.0%
FY202330.3%
FY202437.8%
FY202545.6%
LineFY2025
Cost of revenueCost Of Revenue$11.1B
Gross profitGross Profit$54.1B
Operating expensesOperating Expense$24.4B
Research and developmentResearch And Development$13.3B
Total expensesTotal Expenses$35.5B
Operating incomeOperating Income$29.7B
Pretax incomePretax Income$25.7B

Learn while you research

Academy chapters picked for Eli Lilly and Company and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 48.6, learn when high multiples are justified.6 min read
  3. 03 Growth Investing45% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Leverage RatiosDebt/Equity of 1.60 is elevated, understand what that means for solvency.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →